Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central nervous method, conolidine modulates alternate molecular targets. A Science Developments research identified that conolidine interacts with the atypical chemokine receptor ACK